A Phase 3 clinical trial of vosoritide in children with hypochondroplasia has been marked completed, according to a record dated November 12, 2026. The study, titled "Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia," is registered under identifier NCT06455059. The trial status listed is COMPLETED, and the phase is identified as Phase 3. No results, outcomes, or efficacy data were included in this record. Vosoritide is an approved therapy, and this trial specifically examined its use in children with hypochondroplasia, a distinct skeletal condition. The update reflects only the change in trial status and does not include findings from the study. Readers interested in the broader background of vosoritide, including its approved uses and regulatory history, can consult the compound overview for additional context.
Vosoritide Phase 3 Trial in Hypochondroplasia Completes
See the full vosoritide overview
Source: https://clinicaltrials.gov/study/NCT06455059